This neurotechnology company develops a wearable brain-computer interface device that uses electroencephalography (EEG) and machine learning to detect and track Alzheimer's disease early. The device provides diagnostic insights, enabling timely intervention and treatment for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional electroencephalography (EEG) relies on outdated software and manual interpretation, limiting its clinical utility despite its rich neurological data. Current methods are slow, subjective, and confined to narrow use cases, leaving the full potential of EEG untapped for broader diagnostic applications.
Solution
Axon Interfaces offers MYLIN, an AI-driven software platform that integrates with existing EEG headsets to provide real-time, automated EEG analysis and biomarker extraction. MYLIN transforms underutilized EEG data into a tool for biomarker extraction, therapeutic development, and clinical insight. The platform detects patterns linked to neurodegeneration, psychiatric conditions, and overall brain function by autonomously analyzing resting-state EEG data. MYLIN aims to make brain health more accessible, interpretable, and actionable by revealing patterns invisible to the human eye and supporting earlier diagnosis and treatment monitoring.
Target Audience
The primary users are clinicians, researchers, and pharmaceutical/biotech companies focused on neurology, neurodegeneration, and psychiatric conditions.
Features
- AI-powered platform for automated EEG analysis and biomarker extraction
- Integration with existing EEG headsets, eliminating the need for new hardware
- Real-time, interpretable outputs without manual review
- Biomarker detection for neurodegeneration, psychiatric conditions, and brain function
- Cloud-based platform for scalable, population-level screening
- Target engagement validation, patient population stratification, and development of robust endpoints for neuroactive compounds